The US Food and Drug Administration (FDA) has approved some biomarkers that can predict the efficacy of anti-PD-(L)1 therapy in several cancer types, including PD-L1 expression (assessed using immunohistochemistry), mismatch repair deficient/microsatellite instability-high (dMMR/MSI-high), and tumor mutation burden (TMB). The gene discussed is CD274; the disease is neoplasm.